- Home
- SSM vs CMMB Comparison
SSM vs CMMB Comparison
Compare SSM & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSM
- CMMB
- Stock Information
- Founded
- SSM N/A
- CMMB 2004
- Country
- SSM Germany
- CMMB Israel
- Employees
- SSM 43
- CMMB N/A
- Industry
- SSM
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- SSM
- CMMB Health Care
- Exchange
- SSM Nasdaq
- CMMB Nasdaq
- Market Cap
- SSM 11.9M
- CMMB 13.7M
- IPO Year
- SSM N/A
- CMMB N/A
- Fundamental
- Price
- SSM $7.47
- CMMB $2.80
- Analyst Decision
- SSM
- CMMB Strong Buy
- Analyst Count
- SSM 0
- CMMB 2
- Target Price
- SSM N/A
- CMMB $26.50
- AVG Volume (30 Days)
- SSM N/A
- CMMB 252.0K
- Earning Date
- SSM N/A
- CMMB 11-12-2025
- Dividend Yield
- SSM N/A
- CMMB N/A
- EPS Growth
- SSM N/A
- CMMB N/A
- EPS
- SSM N/A
- CMMB N/A
- Revenue
- SSM N/A
- CMMB N/A
- Revenue This Year
- SSM N/A
- CMMB N/A
- Revenue Next Year
- SSM N/A
- CMMB N/A
- P/E Ratio
- SSM N/A
- CMMB N/A
- Revenue Growth
- SSM N/A
- CMMB N/A
- 52 Week Low
- SSM N/A
- CMMB $2.39
- 52 Week High
- SSM N/A
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- SSM N/A
- CMMB 43.42
- Support Level
- SSM N/A
- CMMB $2.95
- Resistance Level
- SSM N/A
- CMMB $3.29
- Average True Range (ATR)
- SSM 0.00
- CMMB 0.27
- MACD
- SSM 0.00
- CMMB -0.07
- Stochastic Oscillator
- SSM 0.00
- CMMB 11.54
About SSM Sono Group N.V. Ordinary Shares
Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and Services includes Complete Solar Solutions, Solar Charge Controllers, Solar Modules, and Data Services and Engineering Services.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.